In this article we will discuss Anlotinib (Pharmacokinetics-5). So, let’s get started.
Anlotinib has a significantly longer t 1/2 in patients than do most tyrosine kinase inhibitors that have been used clinically to date (i.e., 3–60 h). This extremely long t 1/2 leads to a significant accumulation of plasma anlotinib over time, with a mean accumulation ratio (Rac) of 12 ± 7. A
2-week subchronic dosing regimen resulted in the continuous elevation of plasma anlotinib concentration, with the maximum achieved on day 14. Thereafter, the
plasma level of anlotinib decreased over a 7-day washout period. Based on the above data and toxicity profile, this phase I study recommended a dosing regimen in future studies of 12 mg daily for 2 weeks, followed by a 1-week break.